| 9 | A peptide-based assay discriminates individual antibody response to SARS-CoV-2显示文摘SARS-CoV-2 virus is responsible for the current worldwide coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. Understanding the antibody response to SARS-CoV-2 is crucial for the development of vaccines, therapeutics and public health interventions. However, lack of consistency in methods used to monitor antibody response to SARS-CoV-2 leaves some uncertainty in our fine understanding of the human antibody response mounted following SARS-CoV-2 infection. We developed a peptide-based enzyme-linked immunosorbent assay (ELISA) by selecting 7 synthetic peptides from the spike, membrane, and nucleocapsid protein sequences of SARS-CoV-2, which effectively detects the antibody response mounted by all COVID-19 convalescent tested. Strikingly, the assay shows a profound difference in antibody response among individual subjects, which may have a significant impact on disease severity. Together, our results define an efficient and specific serological assay to consistently measure the antibody response following SARS-CoV-2 infection, as well as help the design of vaccine and therapeuticals for prevention and treatment of COVID-19. | Immacolata Polvere Serena Voccola Gaetano Cardinale Maurizio Fumi Francesca Aquila Alfredina Parrell Jessica Raffaella Madera Romania Stilo Pasquale Vito Tiziana Zotti | 2022 | Genes & Diseases2022，9，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员